



Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science

June 27, 2017

Presentation will cover new data on the long-term efficacy of crofelemer (Mytesi®) based on a supplemental analysis of the ADVENT trial

SAN FRANCISCO--(BUSINESS WIRE)--Jun. 27, 2017-- Napo Pharmaceuticals, Inc., a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), announced today that new crofelemer (Mytesi®) data from a supplemental analysis of the ADVENT trial will be featured in a poster presentation at the 9th International Aids Society (IAS) Conference on HIV Science. The meeting will be held from July 23 to 26, 2017 in Paris, France.

Presentation Title: Long-Term Crofelemer Use Gives Clinically Relevant Reductions in HIV-Related Diarrhea

Presentation by Roger D. MacArthur, MD, Patrick Clay, PharmD, Gary Blick, MD, Roger Waltzman, MD, Margie Bell, MS

Date and Time of Presentation: Wednesday, July 26, 2017, 12:30 – 4:30 p.m.

Dates and Time of Poster Display: Monday, July 24 - Wednesday, July 26, 12:30 – 4:30 p.m.

Location: Poster Exhibition area

Abstract Number: A-854-0101-01472

Launched by Napo Pharmaceuticals in October 2016, Mytesi® is the only antidiarrheal studied in and U.S. FDA-approved for the symptomatic relief of noninfectious diarrhea in adults living with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is a prescription treatment for diarrhea that works differently, by acting locally in the GI tract to normalize the flow of water. Mytesi® does not have drug-drug interactions with ART and has side effects that are similar to placebo.

The IAS Conference on HIV Science features the latest HIV science, including basic, clinical and prevention research. It brings together a broad cross section of HIV professionals from around the world with a focus on implementation – moving scientific advances into practice.

The poster for Napo's presentation will be available on the [IAS website](#) in July after the conference begins.

About Mytesi®

Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at [Mytesi.com](#). Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal *Croton lechleri* tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Proposed Merger

As announced March 31, 2017, Napo and Jaguar Animal Health, Inc. have entered a definitive merger agreement. The proposed merger of Jaguar and Napo remains subject to customary conditions to closing. Upon the consummation of the merger, Jaguar's name will be changed to Jaguar Health, Inc., and Napo will operate as a wholly-owned subsidiary of Jaguar, focused on human health. As previously stated, Jaguar and Napo expect the merger to close by the end of July 2017.

About Napo Pharmaceuticals, Inc.

San Francisco-based Napo Pharmaceuticals, Inc., focuses on the development and commercialization of proprietary pharmaceuticals from rainforest resources for the global marketplace in collaboration with local partners.

For more information, please visit www.napopharma.com.

About Jaguar Animal Health, Inc.

Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar's lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar's prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the *Croton lechleri* tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are Jaguar's lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the *Croton lechleri* tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs.

For more information about Jaguar, please visit www.jaguaranimalhealth.com.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the proposed merger between Jaguar and Napo, the expectation that the proposed merger will close by the end of July 2017, Jaguar's intention to develop species-specific formulations of Neonorm™ in additional target species, and Jaguar's plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Jaguar-JAGX

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170627005820/en/>

Source: Jaguar Animal Health, Inc.

KCSA Strategic Communications

Kate Tumino, 212-896-1252

ktumino@kcsa.com

or

Lisa Lipson, 508-843-6428

llipson@kcsa.com